Improving the effectiveness of Tarlatamab for treating small cell lung cancer
A Novel Approach to Enhance Therapeutic Efficacy of Tarlatamab for Small Cell Lung Cancer Treatment
['FUNDING_R21'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11093082
This study is looking to make the cancer treatment Tarlatamab work better for people with small cell lung cancer by figuring out what helps some patients respond well to it, so they can create more personalized and effective treatment plans.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11093082 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the therapeutic effects of Tarlatamab, a bispecific T-cell engager antibody, for patients with small cell lung cancer (SCLC). The study aims to identify molecular factors that influence how well patients respond to Tarlatamab, which targets specific cancer cells and activates the immune system to fight the tumor. By understanding these drivers of response, the research seeks to optimize treatment strategies and improve patient outcomes. The approach involves analyzing patient samples and utilizing advanced technologies like CRISPR to better tailor therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who have previously received treatment and are seeking new therapeutic options.
Not a fit: Patients with other types of lung cancer or those who have not been previously treated for small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with small cell lung cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with bispecific T-cell engagers in other cancers, indicating potential for success with this novel approach in small cell lung cancer.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WAJAPEYEE, NARENDRA — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: WAJAPEYEE, NARENDRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, cancer antigens, cancer cell, Cancer cell line, cancer metastasis